Newsroom

Newsroom

Press Releases

Date Title and Summary Additional Formats
February 27, 2024
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
MINNEAPOLIS , Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on Tuesday, March 5, 2024
February 22, 2024
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
MINNEAPOLIS , Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its distribution partner, SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), has received
February 20, 2024
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MINNEAPOLIS , Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective February 20, 2024 , the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to two individuals entering into employment with
February 20, 2024
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
Nuwellis to share three presentations highlighting the company’s Aquadex SmartFlow system MINNEAPOLIS , Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its planned
February 6, 2024
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don’t respond to diuretics MINNEAPOLIS , Feb. 06, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc.  (Nasdaq: NUWE), a medical technology company focused on transforming the
January 4, 2024
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies MINNEAPOLIS , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid
Displaying 11 - 16 of 16

 

 

Upcoming Events

More events are coming soon.
jump